Int J Med Sci 2005; 2(4):137-142. doi:10.7150/ijms.2.137 This issue Cite

Research Paper

Evaluation of maternal infusion therapy during pregnancy for fetal development

Dóra Petik, Erzsébet Puhó, Andrew E. Czeizel

Foundation for the Community Control of Hereditary Diseases, Budapest, Hungary

Citation:
Petik D, Puhó E, Czeizel AE. Evaluation of maternal infusion therapy during pregnancy for fetal development. Int J Med Sci 2005; 2(4):137-142. doi:10.7150/ijms.2.137. https://www.medsci.org/v02p0137.htm
Other styles

File import instruction

Abstract

The aim of this project was to study the possible association between maternal infusion treatments during pregnancy and variables of fetal development as well as the occurrence of congenital abnormalities (CA) in a case-control design. The large population-based data set of the Hungarian Case‑Control Surveillance of Congenital Abnormalities (HCCSCA) was evaluated based on the medically recorded infusion treatment during pregnancy. Of 22,843 case pregnant women who had newborns or fetuses with congenital abnormalities, 112 (0.5%), while of 38,151 control pregnant women who had newborn infants without any defects, 262 (0.7%), had infusion treatment during pregnancy. Infusion treatment was more frequent in the control group than in the case group with congenital abnormalities (adjusted POR with 945 95% CI: 0.7, 0.6-0.9) and there was no higher rate of maternal infusion treatments in any congenital abnormality group. Mean gestational age was shorter and mean birth weight was smaller in control newborn infants without CA born to mothers with infusion treatment during pregnancy than in the babies of mothers without infusion treatment. The prevalence of mild intrauterine growth retardation was more frequent in the fetuses of pregnant women with hyperemesis gravidarum treated with infusion. The results of the study suggest that infusion treatment of pregnant women did not associate with a higher risk of congenital abnormalities. In addition, the intravenous infusion of drugs has some, but limited efficacy to prevent the adverse effects of hyperemesis gravidarum and threatened preterm delivery.

Keywords: Infusion treatment, underlying pregnancy complications, congenital abnormalities, preterm birth, intrauterine growth retardation.


Citation styles

APA
Petik, D., Puhó, E., Czeizel, A.E. (2005). Evaluation of maternal infusion therapy during pregnancy for fetal development. International Journal of Medical Sciences, 2(4), 137-142. https://doi.org/10.7150/ijms.2.137.

ACS
Petik, D.; Puhó, E.; Czeizel, A.E. Evaluation of maternal infusion therapy during pregnancy for fetal development. Int. J. Med. Sci. 2005, 2 (4), 137-142. DOI: 10.7150/ijms.2.137.

NLM
Petik D, Puhó E, Czeizel AE. Evaluation of maternal infusion therapy during pregnancy for fetal development. Int J Med Sci 2005; 2(4):137-142. doi:10.7150/ijms.2.137. https://www.medsci.org/v02p0137.htm

CSE
Petik D, Puhó E, Czeizel AE. 2005. Evaluation of maternal infusion therapy during pregnancy for fetal development. Int J Med Sci. 2(4):137-142.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) License. See http://ivyspring.com/terms for full terms and conditions.
Popup Image